UBS Group’s Insmed INSM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $276M | Buy |
2,584,446
+846,965
| +49% | +$103M | 0.04% | 508 |
|
|
2026
Q1 | $284M | Sell |
1,737,481
-130,154
| -7% | -$20M | 0.04% | 454 |
|
|
2025
Q4 | $325M | Buy |
1,867,635
+221,396
| +13% | +$40.4M | 0.05% | 354 |
|
|
2025
Q3 | $237M | Buy |
1,646,239
+1,352,785
| +461% | +$166M | 0.04% | 500 |
|
|
2025
Q2 | $29.5M | Sell |
293,454
-184,182
| -39% | -$14.1M | 0.01% | 1987 |
|
|
2025
Q1 | $36.4M | Buy |
477,636
+71,911
| +18% | +$5.5M | 0.01% | 1761 |
|
|
2024
Q4 | $28M | Buy |
405,725
+95,733
| +31% | +$6.89M | 0.01% | 1980 |
|
|
2024
Q3 | $22.6M | Buy |
309,992
+76,003
| +32% | +$5.61M | ﹤0.01% | 1722 |
|
|
2024
Q2 | $15.7M | Sell |
233,989
-147,074
| -39% | -$5.7M | ﹤0.01% | 1876 |
|
|
2024
Q1 | $10.3M | Buy |
381,063
+80,882
| +27% | +$2.26M | ﹤0.01% | 2245 |
|
|
2023
Q4 | $9.3M | Buy |
300,181
+177,981
| +146% | +$4.62M | ﹤0.01% | 2157 |
|
|
2023
Q3 | $3.09M | Sell |
122,200
-46,643
| -28% | -$1.07M | ﹤0.01% | 3025 |
|
|
2023
Q2 | $3.56M | Sell |
168,843
-3,862
| -2% | -$73.3K | ﹤0.01% | 2916 |
|
|
2023
Q1 | $2.94M | Sell |
172,705
-134,193
| -44% | -$2.61M | ﹤0.01% | 3016 |
|
|
2022
Q4 | $6.13M | Buy |
306,898
+271,443
| +766% | +$5.25M | ﹤0.01% | 2308 |
|
|
2022
Q3 | $763K | Sell |
35,455
-41,397
| -54% | -$993K | ﹤0.01% | 3978 |
|
|
2022
Q2 | $1.52M | Sell |
76,852
-141,490
| -65% | -$2.96M | ﹤0.01% | 3367 |
|
|
2022
Q1 | $5.13M | Buy |
218,342
+30,075
| +16% | +$699K | ﹤0.01% | 2511 |
|
|
2021
Q4 | $5.13M | Buy |
188,267
+97,157
| +107% | +$2.78M | ﹤0.01% | 2784 |
|
|
2021
Q3 | $2.51M | Buy |
91,110
+77,183
| +554% | +$2.02M | ﹤0.01% | 3380 |
|
|
2021
Q2 | $396K | Sell |
13,927
-36,998
| -73% | -$1.1M | ﹤0.01% | 4894 |
|
|
2021
Q1 | $1.73M | Buy |
50,925
+34,633
| +213% | +$1.32M | ﹤0.01% | 3707 |
|
|
2020
Q4 | $542K | Sell |
16,292
-617
| -4% | -$22.5K | ﹤0.01% | 4541 |
|
|
2020
Q3 | $544K | Buy |
16,909
+1,243
| +8% | +$35.7K | ﹤0.01% | 4110 |
|
|
2020
Q2 | $431K | Sell |
15,666
-19,279
| -55% | -$457K | ﹤0.01% | 4269 |
|
|
2020
Q1 | $560K | Buy |
34,945
+8,430
| +32% | +$200K | ﹤0.01% | 3851 |
|
|
2019
Q4 | $633K | Sell |
26,515
-189,140
| -88% | -$3.85M | ﹤0.01% | 4627 |
|
|
2019
Q3 | $3.8M | Buy |
215,655
+152,973
| +244% | +$2.95M | ﹤0.01% | 2641 |
|
|
2019
Q2 | $1.6M | Buy |
62,682
+47,761
| +320% | +$1.33M | ﹤0.01% | 3350 |
|
|
2019
Q1 | $434K | Sell |
14,921
-174,777
| -92% | -$4.53M | ﹤0.01% | 4149 |
|
|
2018
Q4 | $2.49M | Buy |
189,698
+156,399
| +470% | +$2.5M | ﹤0.01% | 2825 |
|
|
2018
Q3 | $674K | Buy |
33,299
+15,247
| +84% | +$344K | ﹤0.01% | 4181 |
|
|
2018
Q2 | $427K | Sell |
18,052
-99,515
| -85% | -$2.56M | ﹤0.01% | 4435 |
|
|
2018
Q1 | $2.65M | Buy |
117,567
+96,897
| +469% | +$2.55M | ﹤0.01% | 2894 |
|
|
2017
Q4 | $645K | Sell |
20,670
-2,251
| -10% | -$66.5K | ﹤0.01% | 4107 |
|
|
2017
Q3 | $715K | Sell |
22,921
-2,193
| -9% | -$41.8K | ﹤0.01% | 3961 |
|
|
2017
Q2 | $431K | Sell |
25,114
-9,500
| -27% | -$162K | ﹤0.01% | 4216 |
|
|
2017
Q1 | $606K | Sell |
34,614
-59,339
| -63% | -$915K | ﹤0.01% | 3904 |
|
|
2016
Q4 | $1.24M | Sell |
93,953
-132,560
| -59% | -$1.81M | ﹤0.01% | 3371 |
|
|
2016
Q3 | $3.29M | Sell |
226,513
-11,246
| -5% | -$141K | ﹤0.01% | 2411 |
|
|
2016
Q2 | $2.34M | Sell |
237,759
-145,051
| -38% | -$1.69M | ﹤0.01% | 2639 |
|
|
2016
Q1 | $4.85M | Sell |
382,810
-381,339
| -50% | -$5.01M | ﹤0.01% | 1894 |
|
|
2015
Q4 | $13.9M | Sell |
764,149
-101,531
| -12% | -$1.79M | 0.01% | 1184 |
|
|
2015
Q3 | $16.1M | Sell |
865,680
-105,373
| -11% | -$2.63M | 0.01% | 1041 |
|
|
2015
Q2 | $23.7M | Sell |
971,053
-157,925
| -14% | -$3.59M | 0.02% | 870 |
|
|
2015
Q1 | $23.5M | Buy |
1,128,978
+15,641
| +1% | +$276K | 0.02% | 862 |
|
|
2014
Q4 | $17.2M | Buy |
+1,113,337
| New | +$15.8M | 0.01% | 1097 |
|
Other funds holding INSM
BBA
DGM
OAG
UBS Group's INSM Position: Q2 2026 in Review
UBS Group increased its Insmed (INSM) stake by 49% in Q2 2026, buying an estimated $103M and bringing the position to 2,584,446 shares worth $276M. The position accounts for 0.04% of the portfolio, ranked #508.
UBS Group first reported a position in INSM in Q4 2014 and has held it in 47 quarters since. The position peaked at $325M in Q4 2025. 665 funds tracked by Wall St. Rank hold INSM as of Q2 2026.
- UBS Group held 2,584,446 shares of Insmed worth $276M as of Q2 2026.
- UBS Group bought 846,965 Insmed shares in Q2 2026, an estimated $103M.
- Insmed made up 0.04% of UBS Group's portfolio in Q2 2026, its #508 holding.
- UBS Group first reported a position in Insmed in Q4 2014 and has held it in 47 quarters since.
- UBS Group's Insmed position peaked at $325M in Q4 2025.
- 665 funds tracked by Wall St. Rank held Insmed as of Q2 2026.
Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.